BACKGROUND:African Americans have a disproportionate burden of hypertension and comorbid disease. Pharmacogenetic markers of blood pressure response have yet to be defined clearly. This study explores the association between G-protein-coupled receptor kinase type 4 (GRK4) variants and blood pressure response to metoprolol among African Americans with early hypertensive nephrosclerosis. METHODS:Participants from the African American Study of Kidney Disease and Hypertension (AASK) trial were genotyped at three GRK4 polymorphisms: R65L, A142V, and A486V. A Cox proportional hazards model, stratified by gender, was used to determine the relationship between GRK4 variants and time to reach a mean arterial pressure (MAP) of 107 mm Hg, adjusted for other predictors of blood pressure response. Potential interactions between the three polymorphisms were explored by analyzing the effects of gene haplotypes and by stratifying the analysis by neighboring sites. RESULTS: The hazard ratio with 95% confidence interval by A142V among men randomized to a usual MAP (102-107 mm Hg) was 1.54 (1.11-2.44; P = 0.0009). The hazard ratio by A142V with R65/L65 or L65/L65 was 2.14 (1.35-3.39; P = 0.001). Haplotype analyses were consistent but inconclusive. There was no association between A142V and blood pressure response among women. CONCLUSIONS: Results suggest a sex-specific relationship between GRK4 A142V and blood pressure response among African-American men with early hypertensive nephrosclerosis. Men with a GRK4 A142 were less responsive to metoprolol if they had a GRK4 L65 variant. The effect of GRK4 variants and blood pressure response to metoprolol should be studied in larger clinical trials.
RCT Entities:
BACKGROUND: African Americans have a disproportionate burden of hypertension and comorbid disease. Pharmacogenetic markers of blood pressure response have yet to be defined clearly. This study explores the association between G-protein-coupled receptor kinase type 4 (GRK4) variants and blood pressure response to metoprolol among African Americans with early hypertensive nephrosclerosis. METHODS:Participants from the African American Study of Kidney Disease and Hypertension (AASK) trial were genotyped at three GRK4 polymorphisms: R65L, A142V, and A486V. A Cox proportional hazards model, stratified by gender, was used to determine the relationship between GRK4 variants and time to reach a mean arterial pressure (MAP) of 107 mm Hg, adjusted for other predictors of blood pressure response. Potential interactions between the three polymorphisms were explored by analyzing the effects of gene haplotypes and by stratifying the analysis by neighboring sites. RESULTS: The hazard ratio with 95% confidence interval by A142V among men randomized to a usual MAP (102-107 mm Hg) was 1.54 (1.11-2.44; P = 0.0009). The hazard ratio by A142V with R65/L65 or L65/L65 was 2.14 (1.35-3.39; P = 0.001). Haplotype analyses were consistent but inconclusive. There was no association between A142V and blood pressure response among women. CONCLUSIONS: Results suggest a sex-specific relationship between GRK4A142V and blood pressure response among African-American men with early hypertensive nephrosclerosis. Men with a GRK4 A142 were less responsive to metoprolol if they had a GRK4 L65 variant. The effect of GRK4 variants and blood pressure response to metoprolol should be studied in larger clinical trials.
Authors: Haidong Zhu; Yanhui Lu; Xiaoling Wang; Harold Snieder; Frank A Treiber; Gregory A Harshfield; Yanbin Dong Journal: Pediatr Res Date: 2006-08-28 Impact factor: 3.756
Authors: Zheng Wang; Ines Armando; Laureano D Asico; Crisanto Escano; Xiaoyan Wang; Quansheng Lu; Robin A Felder; Christine G Schnackenberg; David R Sibley; Gilbert M Eisner; Pedro A Jose Journal: Am J Physiol Heart Circ Physiol Date: 2007-01-26 Impact factor: 4.733
Authors: Xia Yang; Eric E Schadt; Susanna Wang; Hui Wang; Arthur P Arnold; Leslie Ingram-Drake; Thomas A Drake; Aldons J Lusis Journal: Genome Res Date: 2006-07-06 Impact factor: 9.043
Authors: Vibha Bhatnagar; Daniel T O'Connor; Nicholas J Schork; Rany M Salem; Caroline M Nievergelt; Brinda K Rana; Douglas W Smith; George L Bakris; John P Middleton; Keith C Norris; Jackson T Wright; Deanna Cheek; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz Journal: J Hypertens Date: 2007-10 Impact factor: 4.844
Authors: Zhenyu Diao; Laureano D Asico; Van Anthony M Villar; Xiaoxu Zheng; Santiago Cuevas; Ines Armando; Pedro A Jose; Xiaoyan Wang Journal: Free Radic Biol Med Date: 2017-02-09 Impact factor: 7.376
Authors: Andrew C Tiu; Michael D Bishop; Laureano D Asico; Pedro A Jose; Van Anthony M Villar Journal: Curr Hypertens Rep Date: 2017-09 Impact factor: 5.369
Authors: H Sanada; M Yoneda; J Yatabe; S M Williams; J Bartlett; M J White; L N Gordon; R A Felder; G M Eisner; I Armando; P A Jose Journal: Pharmacogenomics J Date: 2015-03-03 Impact factor: 3.550
Authors: Vibha Bhatnagar; Erin P Garcia; Daniel T O'Connor; Victoria H Brophy; John Alcaraz; Erin Richard; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz Journal: Am J Nephrol Date: 2009-11-12 Impact factor: 3.754